Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun:66:101710.
doi: 10.1016/j.canep.2020.101710. Epub 2020 Apr 1.

Impact of preexisting type 2 diabetes mellitus and antidiabetic drugs on all-cause and cause-specific mortality among Medicaid-insured women diagnosed with breast cancer

Wayne R Lawrence  1 , Akiko S Hosler  2 , Margaret Gates Kuliszewski  3 , Matthew C Leinung  4 , Xiuling Zhang  5 , Maria J Schymura  3 , Francis P Boscoe  3
Affiliations

Impact of preexisting type 2 diabetes mellitus and antidiabetic drugs on all-cause and cause-specific mortality among Medicaid-insured women diagnosed with breast cancer

Wayne R Lawrence et al. Cancer Epidemiol. 2020 Jun.

Abstract

Background: We investigated the influence preexisting type 2 diabetes mellitus (T2DM) and antidiabetic drugs have on all-cause and cause-specific mortality among Medicaid-insured women diagnosed with breast cancer.

Methods: 9221 women aged <64 years diagnosed with breast cancer and reported to the New York State (NYS) Cancer Registry from 2004 to 2016 were linked with Medicaid claims. Preexisting T2DM was determined by three diagnosis claims for T2DM with at least one claim prior to breast cancer diagnosis and a prescription claim for an antidiabetic drug within three months following breast cancer diagnosis. Estimated menopausal status was determined by age (premenopausal age <50; postmenopausal age ≥50). Hazard ratios (HR) and 95 % confidence intervals (95 %CI) were calculated with Cox proportional hazards regression, adjusting for confounders.

Results: Women with preexisting T2DM had greater all-cause (HR = 1.40; 95 %CI 1.21, 1.63), cancer-specific (HR = 1.24; 95 %CI 1.04, 1.47), and cardiovascular-specific (HR = 2.46; 95 %CI 1.54, 3.90) mortality hazard compared to nondiabetic women. In subgroup analyses, the association between T2DM and all-cause mortality was found among non-Hispanic White (HR 1.78 95 %CI 1.38, 2.30) and postmenopausal (HR = 1.47; 95 %CI 1.23, 1.77) women, but not among other race/ethnicity groups or premenopausal women. Additionally, compared to women prescribed metformin, all-cause mortality hazard was elevated among women prescribed sulfonylurea (HR = 1.44; 95 %CI 1.06, 1.94) or insulin (HR = 1.54; 95 %CI 1.12, 2.11).

Conclusion: Among Medicaid-insured women with breast cancer, those with preexisting T2DM have an increased mortality hazard, especially when prescribed sulfonylurea or insulin. Further research is warranted to determine the role antidiabetic drugs have on survival among women with breast cancer.

Keywords: Breast cancer; Cancer registry; Cardiovascular; Diabetes; Glucose-lowering drugs; Medicaid; Mortality.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors declare no conflict of interest.

Figures

Fig. 1.
Fig. 1.
Cumulative incidence function for all-cause mortality among Medicaid-insured women diagnosed with breast cancer with preexisting type 2 diabetes mellitus and without diabetes.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Gregg EW, Cheng YJ, Srinivasan M, Lin J, Geiss LS, Albright AL, Imperatore G, Trends in cause-specific mortality among adults with and without diagnosed diabetes in the USA: an epidemiological analysis of linked national survey and vital statistics data, Lancet (London, England) 391 (2018) 2430–2440, 10.1016/S0140-6736(18)30314-3. - DOI - PubMed
    1. Rao Kondapally Seshasai S, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, Whincup PH, Mukamal KJ, Gillum RF, Holme I, Njølstad I, Fletcher A, Nilsson P, Lewington S, Collins R, Gudnason V, Thompson SG, Sattar N, Selvin E, Hu FB, Danesh J, Emerging Risk Factors Collaboration, Diabetes mellitus, fasting glucose, and risk of cause-specific death, N. Engl. J. Med 364 (2011) 829–841, 10.1056/NEJMoa1008862. - DOI - PMC - PubMed
    1. Peairs KS, Barone BB, Snyder CF, Yeh H-C, Stein KB, Derr RL, Brancati FL, Wolff AC, Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis, J. Clin. Oncol 29 (2011) 40–46, 10.1200/JCO.2009.27.3011. - DOI - PMC - PubMed
    1. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D, Diabetes and cancer: a consensus report, CA Cancer J. Clin 60 (2010) 207–221, 10.3322/caac.20078. - DOI - PubMed
    1. Lipscombe LL, Goodwin PJ, Zinman B, McLaughlin JR, Hux JE, Diabetes mellitus and breast cancer: a retrospective population-based cohort study, Breast Cancer Res. Treat 98 (2006) 349–356, 10.1007/s10549-006-9172-5. - DOI - PubMed

Publication types

Substances